Brain Tumor Res Treat.  2023 Jan;11(1):39-46. 10.14791/btrt.2022.0043.

The Role of Hypoxia in Brain Tumor Immune Responses

• Park JH
• Lee HK

• KMID: 2539328
• DOI: http://doi.org/10.14791/btrt.2022.0043

Abstract

Oxygen is a vital component of living cells. Low levels of oxygen in body tissues, known as hypoxia, can affect multiple cellular functions across a variety of cell types and are a hallmark of brain tumors. In the tumor microenvironment, abnormal vasculature and enhanced oxygen consumption by tumor cells induce broad hypoxia that affects not only tumor cell characteristics but also the antitumor immune system. Although some immune reactions require hypoxia, hypoxia generally negatively affects immunity. Hypoxia induces tumor cell invasion, cellular adaptations to hypoxia, and tumor cell radioresistance. In addition, hypoxia limits the efficacy of immunotherapy and hinders antitumor responses. Therefore, understanding the role of hypoxia in the brain tumor, which usually does not respond to immunotherapy alone is important for the development of effective anti-tumor therapies. In this review, we discuss recent evidence supporting the role of hypoxia in the context of brain tumors.

Keyword

Hypoxia; Brain neoplasm; Hypoxia-inducible factor 1; Tumor microenvironment

Figure

• 

  Fig. 1 Molecular mechanism of HIF1α degradation and stabilization. Oxygen-dependent PHD activity hydroxylates HIF1α. Hydroxylation of HIF1α allows VHL to bind to HIF1α. VHL facilitates the recruitment of ubiquitin ligases. Ubiquitinated HIF1α is degraded by the proteasome. Hypoxia stabilizes HIF1α. HIF1α translocates to the nucleus and binds to HIF1β. The HIF dimer regulates transcription of HRE genes. HIF1α, hypoxia-inducible factor 1-alpha; PHD, prolyl hydroxylase domain; VHL, von Hippel-Lindau tumor suppressor protein; HRE, hypoxiaresponse element.

• 

  Fig. 2 Mechanisms of brain tumor immunity. A: Tumor cell death spreads antigens. Antigen presenting cells uptake antigens and migrate to the lymph node. At the lymph node, antigen presenting cells present antigens to the T cells. T cells undergo clonal expansion and activation. Antigen-specific T cells migrate to the tumor site and kill tumor cells. B: Cytotoxic lymphocytes such as CD8 T cells, NK cells, and γδ T cells kill tumor cells. Helper cells, including Th1 promote antitumor immunity. In contrast, suppressor cells such as MDSCs and Tregs suppress antitumor immunity. Phagocytes such as macrophages and neutrophils phagocytose tumor cells or tumor cell debris. MDSC, myeloid-derived suppressor cells; NK, natural killer; Th1, T helper 1; Tregs, regulatory T cells.

• 

  Fig. 3 Role of hypoxia in antitumor immunity. Oxygen tension decreases close to the tumor core. Under normoxia, antitumor immunity occurs normally. Under hypoxia, oxygen deprivation induces tumor cell invasion, radioresistance, and necrosis. Immune cells also undergo hypoxia. The metabolic fitness of immune cells is disrupted. Immunosuppression resulting from M2 macrophage polarization and T cell exhaustion is mediated by hypoxia.

Reference

1. Martínez-Reyes I, Chandel NS. Mitochondrial TCA cycle metabolites control physiology and disease. Nat Commun. 2020; 11:102. PMID: 31900386.

2. Barnett JA. A history of research on yeasts 2: Louis Pasteur and his contemporaries, 1850-1880. Yeast. 2000; 16:755–771. PMID: 10861901.

3. Warburg O. The chemical constitution of respiration ferment. Science. 1928; 68:437–443. PMID: 17782077.

4. Heymans C, Ladon A. Recherches physiologiques et pharmacologiques sur la tête isolée et le centre vague du chien. Arch Internat de Pharmacodyn et de Thérap. 1925; 30:415.

5. Heymans JF, Heymans C. Sur les modifications directes et sur la régulation réflexe de l’activité du centre respiratoire de la tête isolée du chien. Arch Int Pharmacodyn Ther. 1927; 33:273–372.

6. Semenza GL, Nejfelt MK, Chi SM, Antonarakis SE. Hypoxia-inducible nuclear factors bind to an enhancer element located 3’ to the human erythropoietin gene. Proc Natl Acad Sci U S A. 1991; 88:5680–5684. PMID: 2062846.

7. Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A. 1995; 92:5510–5514. PMID: 7539918.

8. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, et al. The tumour suppressor protein VHL targets hypoxiainducible factors for oxygen-dependent proteolysis. Nature. 1999; 399:271–275. PMID: 10353251.

9. Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, et al. HIFα targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science. 2001; 292:464–468. PMID: 11292862.

10. Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, et al. Targeting of HIF-α to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science. 2001; 292:468–472. PMID: 11292861.

11. Erecińska M, Silver IA. Tissue oxygen tension and brain sensitivity to hypoxia. Respir Physiol. 2001; 128:263–276. PMID: 11718758.

12. Beppu T, Kamada K, Yoshida Y, Arai H, Ogasawara K, Ogawa A. Change of oxygen pressure in glioblastoma tissue under various conditions. J Neurooncol. 2002; 58:47–52. PMID: 12160140.

13. Harris AL. Hypoxia--a key regulatory factor in tumour growth. Nat Rev Cancer. 2002; 2:38–47. PMID: 11902584.

14. Thomlinson RH, Gray LH. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer. 1955; 9:539–549. PMID: 13304213.

15. Brown JM, Giaccia AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res. 1998; 58:1408–1416. PMID: 9537241.

16. Taylor CT, Colgan SP. Regulation of immunity and inflammation by hypoxia in immunological niches. Nat Rev Immunol. 2017; 17:774–785. PMID: 28972206.

17. Hendry SA, Farnsworth RH, Solomon B, Achen MG, Stacker SA, Fox SB. The role of the tumor vasculature in the host immune response: implications for therapeutic strategies targeting the tumor microenvironment. Front Immunol. 2016; 7:621. PMID: 28066431.

18. Park JH, Lee HK. Current understanding of hypoxia in glioblastoma multiforme and its response to immunotherapy. Cancers (Basel). 2022; 14:1176. PMID: 35267480.

19. Bertout JA, Patel SA, Simon MC. The impact of O2 availability on human cancer. Nat Rev Cancer. 2008; 8:967–975. PMID: 18987634.

20. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, et al. Overexpression of hypoxia-inducible factor 1α in common human cancers and their metastases. Cancer Res. 1999; 59:5830–5835. PMID: 10582706.

21. Keith B, Johnson RS, Simon MC. HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer. 2011; 12:9–22. PMID: 22169972.

22. Fong GH, Takeda K. Role and regulation of prolyl hydroxylase domain proteins. Cell Death Differ. 2008; 15:635–641. PMID: 18259202.

23. Cockman ME, Masson N, Mole DR, Jaakkola P, Chang GW, Clifford SC, et al. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem. 2000; 275:25733–25741. PMID: 10823831.

24. Kallio PJ, Pongratz I, Gradin K, McGuire J, Poellinger L. Activation of hypoxia-inducible factor 1alpha: posttranscriptional regulation and conformational change by recruitment of the Arnt transcription factor. Proc Natl Acad Sci U S A. 1997; 94:5667–5672. PMID: 9159130.

25. Liu Z, Han L, Dong Y, Tan Y, Li Y, Zhao M, et al. EGFRvIII/integrin β3 interaction in hypoxic and vitronectinenriching microenvironment promote GBM progression and metastasis. Oncotarget. 2016; 7:4680–4694. PMID: 26717039.

26. Braunstein S, Karpisheva K, Pola C, Goldberg J, Hochman T, Yee H, et al. A hypoxia-controlled cap-dependent to cap-independent translation switch in breast cancer. Mol Cell. 2007; 28:501–512. PMID: 17996713.

27. Bouchecareilh M, Higa A, Fribourg S, Moenner M, Chevet E. Peptides derived from the bifunctional kinase/RNase enzyme IRE1α modulate IRE1α activity and protect cells from endoplasmic reticulum stress. FASEB J. 2011; 25:3115–3129. PMID: 21680894.

28. Liu CY, Schröder M, Kaufman RJ. Ligand-independent dimerization activates the stress response kinases IRE1 and PERK in the lumen of the endoplasmic reticulum. J Biol Chem. 2000; 275:24881–24885. PMID: 10835430.

29. Wilson DF, Rumsey WL, Green TJ, Vanderkooi JM. The oxygen dependence of mitochondrial oxidative phosphorylation measured by a new optical method for measuring oxygen concentration. J Biol Chem. 1988; 263:2712–2718. PMID: 2830260.

30. Hayek I, Fischer F, Schulze-Luehrmann J, Dettmer K, Sobotta K, Schatz V, et al. Limitation of TCA cycle intermediates represents an oxygen-independent nutritional antibacterial effector mechanism of macrophages. Cell Rep. 2019; 26:3502–3510.e6. PMID: 30917307.

31. Fuhrmann DC, Brüne B. Mitochondrial composition and function under the control of hypoxia. Redox Biol. 2017; 12:208–215. PMID: 28259101.

32. Liu L, Feng D, Chen G, Chen M, Zheng Q, Song P, et al. Mitochondrial outer-membrane protein FUNDC1 mediates hypoxia-induced mitophagy in mammalian cells. Nat Cell Biol. 2012; 14:177–185. PMID: 22267086.

33. Nakazawa MS, Keith B, Simon MC. Oxygen availability and metabolic adaptations. Nat Rev Cancer. 2016; 16:663–673. PMID: 27658636.

34. Lee P, Chandel NS, Simon MC. Cellular adaptation to hypoxia through hypoxia inducible factors and beyond. Nat Rev Mol Cell Biol. 2020; 21:268–283. PMID: 32144406.

35. Abou Khouzam R, Brodaczewska K, Filipiak A, Zeinelabdin NA, Buart S, Szczylik C, et al. Tumor hypoxia regulates immune escape/invasion: influence on angiogenesis and potential impact of hypoxic biomarkers on cancer therapies. Front Immunol. 2021; 11:613114. PMID: 33552076.

36. Zahra FT, Sajib MS, Ichiyama Y, Akwii RG, Tullar PE, Cobos C, et al. Endothelial RhoA GTPase is essential for in vitro endothelial functions but dispensable for physiological in vivo angiogenesis. Sci Rep. 2019; 9:11666. PMID: 31406143.

37. Wang H, Keiser JA. Vascular endothelial growth factor upregulates the expression of matrix metalloproteinases in vascular smooth muscle cells: role of flt-1. Circ Res. 1998; 83:832–840. PMID: 9776730.

38. Marampon F, Gravina GL, Zani BM, Popov VM, Fratticci A, Cerasani M, et al. Hypoxia sustains glioblastoma radioresistance through ERKs/DNA-PKcs/HIF-1α functional interplay. Int J Oncol. 2014; 44:2121–2131. PMID: 24676782.

39. Takubo K, Goda N, Yamada W, Iriuchishima H, Ikeda E, Kubota Y, et al. Regulation of the HIF-1alpha level is essential for hematopoietic stem cells. Cell Stem Cell. 2010; 7:391–402. PMID: 20804974.

40. Guitart AV, Subramani C, Armesilla-Diaz A, Smith G, Sepulveda C, Gezer D, et al. Hif-2α is not essential for cell-autonomous hematopoietic stem cell maintenance. Blood. 2013; 122:1741–1745. PMID: 23894152.

41. Krock BL, Eisinger-Mathason TS, Giannoukos DN, Shay JE, Gohil M, Lee DS, et al. The aryl hydrocarbon receptor nuclear translocator is an essential regulator of murine hematopoietic stem cell viability. Blood. 2015; 125:3263–3272. PMID: 25855602.

42. Cho SH, Raybuck AL, Stengel K, Wei M, Beck TC, Volanakis E, et al. Germinal centre hypoxia and regulation of antibody qualities by a hypoxia response system. Nature. 2016; 537:234–238. PMID: 27501247.

43. Abbott RK, Thayer M, Labuda J, Silva M, Philbrook P, Cain DW, et al. Germinal center hypoxia potentiates immunoglobulin class switch recombination. J Immunol. 2016; 197:4014–4020. PMID: 27798169.

44. Wagner G, Levin R. Oxygen tension of the vaginal surface during sexual stimulation in the human. Fertil Steril. 1978; 30:50–53. PMID: 581075.

45. Kozak KR, Abbott B, Hankinson O. ARNT-deficient mice and placental differentiation. Dev Biol. 1997; 191:297–305. PMID: 9398442.

46. Wakeland AK, Soncin F, Moretto-Zita M, Chang CW, Horii M, Pizzo D, et al. Hypoxia directs human extravillous trophoblast differentiation in a hypoxia-inducible factor–dependent manner. Am J Pathol. 2017; 187:767–780. PMID: 28167044.

47. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013; 39:1–10. PMID: 23890059.

48. Ferris ST, Durai V, Wu R, Theisen DJ, Ward JP, Bern MD, et al. cDC1 prime and are licensed by CD4+ T cells to induce anti-tumour immunity. Nature. 2020; 584:624–629. PMID: 32788723.

49. Kersten K, Hu KH, Combes AJ, Samad B, Harwin T, Ray A, et al. Spatiotemporal co-dependency between macrophages and exhausted CD8+ T cells in cancer. Cancer Cell. 2022; 40:624–638.e9. PMID: 35623342.

50. Cornel AM, Mimpen IL, Nierkens S. MHC class I downregulation in cancer: underlying mechanisms and potential targets for cancer immunotherapy. Cancers (Basel). 2020; 12:1760. PMID: 32630675.

51. Okazaki T, Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol. 2007; 19:813–824. PMID: 17606980.

52. Akdis CA, Blaser K. Mechanisms of interleukin-10-mediated immune suppression. Immunology. 2001; 103:131–136. PMID: 11412299.

53. Joyce JA, Fearon DT. T cell exclusion, immune privilege, and the tumor microenvironment. Science. 2015; 348:74–80. PMID: 25838376.

54. Kalafati L, Mitroulis I, Verginis P, Chavakis T, Kourtzelis I. Neutrophils as orchestrators in tumor development and metastasis formation. Front Oncol. 2020; 10:581457. PMID: 33363012.

55. Jaiswal S, Chao MP, Majeti R, Weissman IL. Macrophages as mediators of tumor immunosurveillance. Trends Immunol. 2010; 31:212–219. PMID: 20452821.

56. Kim HJ, Park JH, Kim HC, Kim CW, Kang I, Lee HK. Blood monocyte-derived CD169+ macrophages contribute to antitumor immunity against glioblastoma. Nat Commun. 2022; 13:6211. PMID: 36266311.

57. Godfrey DI, Le Nours J, Andrews DM, Uldrich AP, Rossjohn J. Unconventional T cell targets for cancer immunotherapy. Immunity. 2018; 48:453–473. PMID: 29562195.

58. Park JH, Lee HK. Function of γδ T cells in tumor immunology and their application to cancer therapy. Exp Mol Med. 2021; 53:318–327. PMID: 33707742.

59. Shirai Y. On the transplantation of the rat sarcoma in adult heterogenous animals. Jap Med World. 1921; 1:14–15.

60. Murphy JB, Sturm E. Conditions determining the transplantability of tissues in the brain. J Exp Med. 1923; 38:183–197. PMID: 19868782.

61. Medawar PB. Immunity to homologous grafted skin; the fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye. Br J Exp Pathol. 1948; 29:58–69. PMID: 18865105.

62. Carson MJ, Doose JM, Melchior B, Schmid CD, Ploix CC. CNS immune privilege: hiding in plain sight. Immunol Rev. 2006; 213:48–65. PMID: 16972896.

63. Retzius MG, Key A. Studien in der Anatomie des Nervensystems und des Bindegewebes, von Axel Key und Gustaf Retzius. Stockholm: Samson & Wallin;1875.

64. Lukić IK, Gluncić V, Ivkić G, Hubenstorf M, Marusić A. Virtual dissection: a lesson from the 18th century. Lancet. 2003; 362:2110–2113. PMID: 14697818.

65. Mascagni P, Sanctius C. Vasorum lymphaticorum corporis humani historia et ichnographia. Siena: ex Typographia Pazzini Carli;1787.

66. Louveau A, Smirnov I, Keyes TJ, Eccles JD, Rouhani SJ, Peske JD, et al. Structural and functional features of central nervous system lymphatic vessels. Nature. 2015; 523:337–341. PMID: 26030524.

67. Aspelund A, Antila S, Proulx ST, Karlsen TV, Karaman S, Detmar M, et al. A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules. J Exp Med. 2015; 212:991–999. PMID: 26077718.

68. Iliff JJ, Wang M, Liao Y, Plogg BA, Peng W, Gundersen GA, et al. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid β. Sci Transl Med. 2012; 4:147ra111.

69. Mazzitelli JA, Smyth LCD, Cross KA, Dykstra T, Sun J, Du S, et al. Cerebrospinal fluid regulates skull bone marrow niches via direct access through dural channels. Nat Neurosci. 2022; 25:555–560. PMID: 35301477.

70. Hsu M, Rayasam A, Kijak JA, Choi YH, Harding JS, Marcus SA, et al. Neuroinflammation-induced lymphangiogenesis near the cribriform plate contributes to drainage of CNS-derived antigens and immune cells. Nat Commun. 2019; 10:229. PMID: 30651548.

71. Rustenhoven J, Drieu A, Mamuladze T, de Lima KA, Dykstra T, Wall M, et al. Functional characterization of the dural sinuses as a neuroimmune interface. Cell. 2021; 184:1000–1016.e27. PMID: 33508229.

72. Mohammad MG, Tsai VW, Ruitenberg MJ, Hassanpour M, Li H, Hart PH, et al. Immune cell trafficking from the brain maintains CNS immune tolerance. J Clin Invest. 2014; 124:1228–1241. PMID: 24569378.

73. Furtado D, Björnmalm M, Ayton S, Bush AI, Kempe K, Caruso F. Overcoming the blood–brain barrier: the role of nanomaterials in treating neurological diseases. Adv Mater. 2018; 30:e1801362. PMID: 30066406.

74. Duan Q, Zhang H, Zheng J, Zhang L. Turning cold into hot: firing up the tumor microenvironment. Trends Cancer. 2020; 6:605–618. PMID: 32610070.

75. Leone RD, Powell JD. Metabolism of immune cells in cancer. Nat Rev Cancer. 2020; 20:516–531. PMID: 32632251.

76. Bhandari V, Hoey C, Liu LY, Lalonde E, Ray J, Livingstone J, et al. Molecular landmarks of tumor hypoxia across cancer types. Nat Genet. 2019; 51:308–318. PMID: 30643250.

77. Scharping NE, Menk AV, Whetstone RD, Zeng X, Delgoffe GM. Efficacy of PD-1 blockade is potentiated by metformin-induced reduction of tumor hypoxia. Cancer Immunol Res. 2017; 5:9–16. PMID: 27941003.

78. Miska J, Lee-Chang C, Rashidi A, Muroski ME, Chang AL, Lopez-Rosas A, et al. HIF-1α is a metabolic switch between glycolytic-driven migration and oxidative phosphorylation-driven immunosuppression of Tregs in glioblastoma. Cell Rep. 2019; 27:226–237.e4. PMID: 30943404.

79. Park JH, Kim HJ, Kim CW, Kim HC, Jung Y, Lee HS, et al. Tumor hypoxia represses γδ T cell-mediated antitumor immunity against brain tumors. Nat Immunol. 2021; 22:336–346. PMID: 33574616.

80. Kim AR, Choi SJ, Park J, Kwon M, Chowdhury T, Yu HJ, et al. Spatial immune heterogeneity of hypoxia-induced exhausted features in high-grade glioma. Oncoimmunology. 2022; 11:2026019. PMID: 35036078.

81. Shehade H, Acolty V, Moser M, Oldenhove G. Cutting edge: hypoxia-inducible factor 1 negatively regulates Th1 function. J Immunol. 2015; 195:1372–1376. PMID: 26179900.

82. Noman MZ, Desantis G, Janji B, Hasmim M, Karray S, Dessen P, et al. PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med. 2014; 211:781–790. PMID: 24778419.

83. Scharping NE, Rivadeneira DB, Menk AV, Vignali PDA, Ford BR, Rittenhouse NL, et al. Mitochondrial stress induced by continuous stimulation under hypoxia rapidly drives T cell exhaustion. Nat Immunol. 2021; 22:205–215. PMID: 33398183.

84. Zheng X, Qian Y, Fu B, Jiao D, Jiang Y, Chen P, et al. Mitochondrial fragmentation limits NK cell-based tumor immunosurveillance. Nat Immunol. 2019; 20:1656–1667. PMID: 31636463.

85. Najjar YG, Menk AV, Sander C, Rao U, Karunamurthy A, Bhatia R, et al. Tumor cell oxidative metabolism as a barrier to PD-1 blockade immunotherapy in melanoma. JCI Insight. 2019; 4:e124989. PMID: 30721155.

86. Park JH, Kang I, Kim HC, Lee Y, Lee SK, Lee HK. Obesity enhances antiviral immunity in the genital mucosa through a microbiota-mediated effect on γδ T cells. Cell Rep. 2022; 41:111594. PMID: 36351403.

87. Watson MJ, Vignali PDA, Mullett SJ, Overacre-Delgoffe AE, Peralta RM, Grebinoski S, et al. Metabolic support of tumour-infiltrating regulatory T cells by lactic acid. Nature. 2021; 591:645–651. PMID: 33589820.

88. Guo X, Xue H, Shao Q, Wang J, Guo X, Chen X, et al. Hypoxia promotes glioma-associated macrophage infiltration via periostin and subsequent M2 polarization by upregulating TGF-beta and M-CSFR. Oncotarget. 2016; 7:80521–80542. PMID: 27602954.

89. Tan AC, Ashley DM, López GY, Malinzak M, Friedman HS, Khasraw M. Management of glioblastoma: state of the art and future directions. CA Cancer J Clin. 2020; 70:299–312. PMID: 32478924.

90. Minniti G, Niyazi M, Alongi F, Navarria P, Belka C. Current status and recent advances in reirradiation of glioblastoma. Radiat Oncol. 2021; 16:36. PMID: 33602305.

91. Reardon DA, Brandes AA, Omuro A, Mulholland P, Lim M, Wick A, et al. Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial. JAMA Oncol. 2020; 6:1003–1010. PMID: 32437507.

92. Dewan MZ, Galloway AE, Kawashima N, Dewyngaert JK, Babb JS, Formenti SC, et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res. 2009; 15:5379–5388. PMID: 19706802.

93. Omuro A, Brandes AA, Carpentier AF, Idbaih A, Reardon DA, Cloughesy T, et al. Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: an international randomized phase III trial. Neuro Oncol. 2023; 25:123–134. PMID: 35419607.

94. Song E, Mao T, Dong H, Boisserand LSB, Antila S, Bosenberg M, et al. VEGF-C-driven lymphatic drainage enables immunosurveillance of brain tumours. Nature. 2020; 577:689–694. PMID: 31942068.

95. Hu X, Deng Q, Ma L, Li Q, Chen Y, Liao Y, et al. Meningeal lymphatic vessels regulate brain tumor drainage and immunity. Cell Res. 2020; 30:229–243. PMID: 32094452.

96. Wang X, Guo G, Guan H, Yu Y, Lu J, Yu J. Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma. J Exp Clin Cancer Res. 2019; 38:87. PMID: 30777100.

97. Iwama S, De Remigis A, Callahan MK, Slovin SF, Wolchok JD, Caturegli P. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci Transl Med. 2014; 6:230ra45.

98. Pyonteck SM, Akkari L, Schuhmacher AJ, Bowman RL, Sevenich L, Quail DF, et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med. 2013; 19:1264–1272. PMID: 24056773.

99. von Roemeling CA, Wang Y, Qie Y, Yuan H, Zhao H, Liu X, et al. Therapeutic modulation of phagocytosis in glioblastoma can activate both innate and adaptive antitumour immunity. Nat Commun. 2020; 11:1508. PMID: 32198351.

100. Butowski N, Colman H, De Groot JF, Omuro AM, Nayak L, Wen PY, et al. Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study. Neuro Oncol. 2016; 18:557–564. PMID: 26449250.

101. Schoch HJ, Fischer S, Marti HH. Hypoxia-induced vascular endothelial growth factor expression causes vascular leakage in the brain. Brain. 2002; 125(Pt 11):2549–2557. PMID: 12390979.

102. Rapisarda A, Melillo G. Role of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies. Drug Resist Updat. 2009; 12:74–80. PMID: 19394890.

103. Horsman MR, Overgaard J. The impact of hypoxia and its modification of the outcome of radiotherapy. J Radiat Res. 2016; 57 Suppl 1:i90–i98. PMID: 26983987.

104. Strowd RE, Ellingson BM, Wen PY, Ahluwalia MS, Piotrowski AF, Desai AS, et al. Safety and activity of a first-in-class oral HIF2-alpha inhibitor, PT2385, in patients with first recurrent glioblastoma (GBM). J Clin Oncol. 2019; 37:2027.